Study design (if review, criteria of inclusion for studies)
Systematic review
Participants
Studies reporting nasal endoscopic outcomes using validated scoring systems before and after CFTR modulator therapy were included.
Interventions
CFTR modulator therapy
Outcome measures
Rhinosinusitis and nasal polyposis. Endoscopic scores, including the Modified Lund-Kennedy scale
Main results
Out of 232 identified records, 10 studies met inclusion criteria, representing populations from six countries. Most studies assessed triple therapy (Elexacaftor/Tezacaftor/Ivacaftor). Endoscopic scores, including the Modified Lund-Kennedy scale, showed significant reductions in nasal polyps, mucosal edema, and discharge. Pediatric and adult groups benefited alike, with triple therapy proving more effective than dual or monotherapy. Secondary outcomes included improved pulmonary function, weight gain, and olfactory recovery.
Authors' conclusions
This review demonstrates that CFTR modulators provide significant benefits for sinonasal disease in CF, reinforcing their role as a comprehensive therapeutic approach addressing both upper airway and systemic disease burdens.